Recombinant 2019-nCoV Papain-Like Protease
- Cat. No.：EPT114
- Price：USD $ 5,400.00
- Clicks：1433
Product Detail
Basic Information
| Size | 50ug |
|---|
| Expression Host | E.coli |
|---|
| Tag | NA |
|---|
Physical Properties
| Molecular Weight | 35.8 KDa |
|---|
| Apparent Molecular Weight | 34 KDa, reducing conditions |
|---|
| Form | Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 10 mM 2-Mercaptoethanol, 20% Glycerol, pH 7.5. |
|---|
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
|---|
Activity & Endotoxin
| Activity | Measured by its ability to convert the fluorogenic peptide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) to RLRGG and 7-amino-4-methylcoumarin (AMC). The Specific Activity is 241.7 pmol/min/μg. |
|---|
Storage & Shipping
| Storage | Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles. |
|---|
| Shipping Condition | The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below. |
|---|
Detailed Description
| Background | Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons. |
|---|
